The latest ANSM analyzes have led the committee to reaffirm its wish for a European review of all cases of Parsonage-Turner syndrome and acquired haemophilia, declared with messenger RNA vaccines against Covid-19 .
If the vaccination pass is (almost) no longer required anywhere, the fact remains that the vaccination campaign against Covid-19 continues. And since the start of monitoring the side effects of the various vaccines inoculated against the coronavirus, in particular Pfizer, 18 cases of acquired hemophilia were received and analyzed by the National Drug Safety Agencywe learn in the last report dated March 18, 2022. As a reminder, 3 cases had been presented in report N°15, 6 cases in report N°17, and 10 cases in report 18. The latter had leads to the conclusion: “Also at this stage, the role of the vaccine in the occurrence of these “acquired haemophilias” cannot be excluded.”
In the fifteenth ANSM report already, covering the period from April 30 to May 13, cases of acquired hemophilia had been identified. These cases occurred within a few days to a month, in people over the age of 75, states franceinfo.
What these 18 cases show
18 cases of acquired hemophilia were analyzed. 10 women, 8 men, average age 75, including 2 over the period. The clinical manifestations are mainly multiple hematomas and/or bruises. They occurred in 5 cases during the first dose, in 12 cases during the second dose, and in one case after the booster dose. All these cases required emergency treatment in specialized hospital departments. Three cases were of fatal evolution, precise MyVaccines.
Additional Information from MyVaccines
Overall, the number of adverse events following vaccination is very low when compared to the very high number of people vaccinated. The regular publication of post-vaccination adverse event monitoring data is a guarantee of transparency. However, a post-vaccination adverse event is not synonymous with an adverse reaction attributable to the vaccine, even if the two terms are often used interchangeably, temporize the site MyVaccines.net.
What is acquired hemophilia?
Acquired hemophilia is a rare non-hereditary bleeding disorder due to the presence of antibodies (auto-antibodies) directed against a coagulation factor (factor VIII) which reduce its coagulant activity to an often very low rate. An antibody is a complex protein used by the immune system to detect and neutralize agents recognized as pathogens in a specific way (germs, viruses, etc.). When the recognized agent is one of the constituents of its own organism, we speak of auto-antibodies, specifies the French National Society of Internal Medicine on its website.
In 2021, around 8,000 French people suffered from hemophilia, reports Top Health.
What are the symptoms ?
“Hemophilia is characterized by longer but not heavier bleeding” notes Pr. Négrier to our colleagues from Top Health. In the event of a cut (with a kitchen knife, for example), the bleeding will last longer in a person with hemophilia.
Hemophiliacs can also suffer from bleeding in the joints when they bump into furniture, when they fall. The blood then accumulates inside the “articular bags”, like internal “bruises”. The joints most commonly affected are the knees, ankles and elbows.
The “mainstream” treatment of hemophilia (type A or type B) is based on the regular administration of the missing coagulation factor (factor VIII or factor IX) by the intravenous route: on average, the administration is done 2 to 3 times a week, and it only lasts a few minutes, says the French National Society of Internal Medicine.